Clincosm LogoSign in Get a demo

IP-VAC: Study of the Impact of an Intervention Performed by a Clinical Pharmacist on Patients at Risk of Pneumococcal Infection at the End of Hospitalization

Sponsor
Centre Hospitalier Universitaire de Nīmes (Other)
Overall Status
Completed
CT.gov ID
NCT04734925
Collaborator
(none)
167
Enrollment
1
Location
7.7
Actual Duration (Months)
21.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In France, Streptococcus pneumoniae is the leading agent involved in community-acquired bacterial pneumopathies and bacterial meningitis. The frequency of these infections is increasing in at-risk subjects. Paradoxically, pneumococcal vaccination coverage in this type of patient is limited at the national level, even though the French High Council for Public Health (HCSP) has been extending the 13-valent conjugate and 23-valent non-conjugate double vaccination in this target population since March 2017.

These patients generally benefit from regular medical follow-up involving several health professionals in hospital or outpatient clinics. In spite of this, one of the factors identified as a hindrance to pneumococcal vaccination is the absence of a proposal from the doctor.

We would like to assess compliance with the recommendations for pneumococcal vaccination according to the High Council of Public Health (HCSP) in at-risk patients leaving hospital. We also wish to measure the potential impact of an intervention by the clinical pharmacist on the application of these recommendations.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    167 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Study of the Impact of an Intervention Performed by a Clinical Pharmacist on Patients at Risk of Pneumococcal Infection at the End of Hospitalization
    Actual Study Start Date :
    Mar 1, 2020
    Actual Primary Completion Date :
    Oct 22, 2020
    Actual Study Completion Date :
    Oct 22, 2020

    Outcome Measures

    Primary Outcome Measures

    1. vaccine protocols dispensed by dispensing pharmacists. [3 month]

      number of vaccine protocols

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Hospitalization in one of the departments participating in the study

    • At risk of pneumococcal infection according to HCSP recommendations (1)

    • Negative pneumococcal vaccination status

    • Adult patient (≥18 years old)

    Exclusion Criteria:

    • Under safeguard of justice

    • Unable to receive informed information

    • Patient having objected to the use of their data.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chu Nimes Nîmes France 30029

    Sponsors and Collaborators

    • Centre Hospitalier Universitaire de Nīmes

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Centre Hospitalier Universitaire de Nīmes
    ClinicalTrials.gov Identifier:
    NCT04734925
    Other Study ID Numbers:
    • LOCAL/2019/DF-01
    First Posted:
    Feb 2, 2021
    Last Update Posted:
    Feb 2, 2021
    Last Verified:
    Jan 1, 2021
    Keywords provided by Centre Hospitalier Universitaire de Nīmes
    antipneumococcal
    Additional relevant MeSH terms:
    Pneumococcal Infections

    Study Results

    No Results Posted as of Feb 2, 2021